TUBERCOLOSISAgis Terzidis, Paediatrician Spyridon Gialamas, Medical Doctor

SEMINAR ON TROPICAL AND TRAVEL MEDICINE AT TTCIH

IFAKARA 25 JUNE 2009

Estimated TB incidence rates, by country, 2007

Source: WHO

Trends in estimated incidence rates in nine subregions, 1990-2007

Source: WHO

Progress towards the 70% case-detection target

Source: WHO

Tuberculosis supranational reference laboratory network, 2007

Source: WHO

Countries that had reported at least one case of extensively drug-resistant TB

Source: WHO

Global Fund commitments for TB control by region, as of end 2008

Western Pacific Region20% (US$ 755 million)

African Region29% (US$ 1131 million)

Southeast Asia Region22% (US$ 867 million)

European Region13% (US$ 502 million)

Region of the Americas6% (US$ 229 million)

Eastern Mediterranean Region10% (US$ 382 million)

Source: WHO

Objectives for 2006–2015 of the WorkingGroup on New TB Diagnostics:

• address existing gaps in knowledge that are obstructing development of new diagnostic tools

• develop and evaluate a portfolio of new diagnostic tools and demonstrate their impact

• implement new diagnostic tools and ensure access to them

Source: WHO

Strategic plan for 2006–2015 of the WorkingGroup on New TB Drugs:

• Identification and validation of new targets for drugs, and candidate compounds

• drug development• planning and execution of more effective clinical trials,

including identification of improved biomarkers and methods of assessing latent disease

• clear and efficient regulatory guidance

Source: WHO

Strategic plan for 2006–2015 of the WorkingGroup on TB Vaccines:

• maintain and improve BCG vaccination programmes. The next generation of new vaccines introduced as an addition to BCG vaccines

• expand discovery and translation research on vaccines (“keeping the pipeline filled”)

• facilitate preclinical development of new vaccines• build capacity at vaccine trial sites, providing opportunities

for training and capacity strengthening

AHSANTENI